Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to Yujin LiShirong ZhuXiaomei Hu Review Article Open access 24 April 2020 Pages: 1161 - 1176
Management of myelofibrosis after ruxolitinib failure Claire N HarrisonNicolaas SchaapRuben A Mesa Review Article Open access 20 March 2020 Pages: 1177 - 1191
How to treat myelodysplastic syndrome with clinical features resembling Behçet syndrome: a case-based systematic review Umut YilmazMuhlis Cem ArAykut Ferhat Celik Review Article 05 March 2020 Pages: 1193 - 1203
Mechanism of thrombocytopenia in COVID-19 patients Panyang XuQi ZhouJiancheng Xu Review Article Open access 15 April 2020 Pages: 1205 - 1208
Red blood cell consumption in a large cohort of patients with thalassaemia: a retrospective analysis of main predictors Paolo RicchiAntonella MeloniAldo Filosa Original Article 04 May 2020 Pages: 1209 - 1215
Outcomes related to intravenous fluid administration in sickle cell patients during vaso-occlusive crisis Daria GautJennifer JonesRoswell Quinn Original Article 04 May 2020 Pages: 1217 - 1223
Sickle cell anemia in the state of Maranhão: a haplotype study Ademilton Costa AlvesVerônica Avena Lisboa da SilvaRaimundo Antônio Gomes de Oliveira Original Article 04 May 2020 Pages: 1225 - 1230
Immunodeficiency risk score for prediction of mortality by parainfluenza virus infection in patients with hematologic malignancy Jeongsoo LeeJiwon JungSung-Han Kim Original Article 07 May 2020 Pages: 1231 - 1239
Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia Tim H. BrümmendorfCarlo Gambacorti-PasseriniCarla Mamolo Original Article Open access 19 April 2020 Pages: 1241 - 1249
Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma Magdalini MigkouIrit AviviMeletios A. Dimopoulos Original Article 19 April 2020 Pages: 1251 - 1255
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period Evangelos TerposIoannis Ntanasis-StathopoulosMeletios A. Dimopoulos Original Article 07 May 2020 Pages: 1257 - 1264
Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials Somedeb BallTapas Ranjan BeheraRajshekhar Chakraborty Original Article 07 May 2020 Pages: 1265 - 1271
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study Yael C. CohenHila MagenIrit Avivi Original Article 20 March 2020 Pages: 1273 - 1281
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis Sang Eun YoonSeok Jin KimWon Seog Kim Original Article Open access 24 April 2020 Pages: 1283 - 1291
Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas Joon Young HurYeon Jeong KimWon Seog Kim Original Article 15 April 2020 Pages: 1293 - 1302
Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma Yue ChaiFei QiMei Dong Original Article 24 April 2020 Pages: 1303 - 1309
Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis Shu-Yun MaXiao-Peng TianQing-Qing Cai Original Article 13 April 2020 Pages: 1311 - 1319
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients Domenico AlbanoAngelica MazzolettiFrancesco Bertagna Original Article 24 April 2020 Pages: 1321 - 1330
Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma Xiao DingWenyang HuangFengyan Jin Original Article 08 May 2020 Pages: 1331 - 1339
Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide Alice GarnierThierry GuillaumePatrice Chevallier Original Article 28 April 2020 Pages: 1341 - 1350
Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century Masamitsu YanadaAkiyoshi TakamiShingo Yano Original Article 04 May 2020 Pages: 1351 - 1360
The management of gynecological complications in long-term survivors after allogeneic hematopoietic cell transplantation—a single-center real-life experience Łukasz KlasaAlicja Sadowska-KlasaJan Maciej Zaucha Original Article Open access 28 April 2020 Pages: 1361 - 1368
Impact of blood pressure early after allogeneic hematopoietic cell transplantation on clinical outcomes Masaharu TamakiHideki NakasoneYoshinobu Kanda Original Article 16 March 2020 Pages: 1369 - 1376
Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation Ivan PasicJeffrey H. LiptonFotios V. Michelis Original Article 07 May 2020 Pages: 1377 - 1387
Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience Ling ZhouZhi-yong GaoDao-pei Lu Original Article 14 April 2020 Pages: 1389 - 1400
A case of idiopathic multicentric Castleman disease presenting with diffuse lung cysts: how to evaluate treatment response? Wanlu MaJian LiLu Zhang Letter to the Editor 07 May 2020 Pages: 1401 - 1402
The concomitance of lymphoma and breast carcinoma in the bone Francesco AutoreIdanna InnocentiLuca Laurenti Letter to the Editor 07 May 2020 Pages: 1403 - 1404
Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion Kyoko YoshiharaSatoshi YoshiharaYoshihiro Fujimori Letter to the Editor 03 March 2020 Pages: 1405 - 1407
Subcutaneous marginal zone lymphoma: an unusual lipoma-like presentation Magda ZanelliMaurizio ZizzoStefano Ascani Letter to the Editor 07 April 2020 Pages: 1409 - 1410
Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia Joseph E. MaakaronMichael P. OzgaAlice S. Mims Letter to the Editor 06 May 2020 Pages: 1411 - 1413
Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia Charu GuptaStefan KaulfussMichael Heuser Letter to the Editor Open access 15 April 2020 Pages: 1415 - 1417
Signals of Th2 immune response from COVID-19 patients requiring intensive care Luca RoncatiVincenzo NasilloGiovanni Riva Letter to the Editor 08 May 2020 Pages: 1419 - 1420